MA55872A - Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires - Google Patents

Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires

Info

Publication number
MA55872A
MA55872A MA055872A MA55872A MA55872A MA 55872 A MA55872 A MA 55872A MA 055872 A MA055872 A MA 055872A MA 55872 A MA55872 A MA 55872A MA 55872 A MA55872 A MA 55872A
Authority
MA
Morocco
Prior art keywords
treatment
ocular diseases
sema3a antibodies
sema3a
antibodies
Prior art date
Application number
MA055872A
Other languages
English (en)
Inventor
Rachel Rebecca Barrett
Kristin Laura Bovat
Rajkumar Ganesan
Priyanka Gupta
Fei Han
Dongmei Liu
Juergen Prestle
Sanjaya Singh
Leo Thomas
Sathyadevi Venkataramani
Helen Haixia Wu
Nina Zippel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA55872A publication Critical patent/MA55872A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA055872A 2019-05-09 2020-05-08 Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires MA55872A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19173454 2019-05-09

Publications (1)

Publication Number Publication Date
MA55872A true MA55872A (fr) 2022-03-16

Family

ID=66476463

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055872A MA55872A (fr) 2019-05-09 2020-05-08 Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires

Country Status (23)

Country Link
US (2) US11267880B2 (fr)
EP (1) EP3966239A1 (fr)
JP (2) JP7314310B2 (fr)
KR (1) KR20220007128A (fr)
CN (1) CN113795509A (fr)
AR (1) AR122266A1 (fr)
AU (1) AU2020267874A1 (fr)
BR (1) BR112021019854A2 (fr)
CA (1) CA3137377A1 (fr)
CL (1) CL2021002795A1 (fr)
CO (1) CO2021014768A2 (fr)
CR (1) CR20210559A (fr)
DO (1) DOP2021000226A (fr)
EA (1) EA202193038A1 (fr)
EC (1) ECSP21082527A (fr)
IL (1) IL287758A (fr)
JO (1) JOP20210300A1 (fr)
MA (1) MA55872A (fr)
MX (1) MX2021013671A (fr)
PE (1) PE20220287A1 (fr)
SG (1) SG11202110842QA (fr)
TW (1) TWI836069B (fr)
WO (1) WO2020225400A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR122266A1 (es) 2019-05-09 2022-08-31 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
US20220127344A1 (en) * 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
EP4314047A1 (fr) * 2021-03-30 2024-02-07 Bayer Aktiengesellschaft Anticorps anti-sema3a et leurs utilisations
CN116790610A (zh) * 2023-05-18 2023-09-22 四川大学 一种治疗骨科疾病的基因及以aav为载体的基因治疗药物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
CA2103059C (fr) 1991-06-14 2005-03-22 Paul J. Carter Methode de production d'anticorps humanises
NZ258392A (en) 1992-11-13 1997-09-22 Idec Pharma Corp Chimeric and radiolabelled antibodies to the b lymphocyte cellsurface antigen bp35 (cd-20) and their use in the treatment of b cell lymphona
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
WO2011055550A1 (fr) * 2009-11-05 2011-05-12 国立大学法人大阪大学 Agent thérapeutique pour des maladies auto-immunes ou une allergie et procédé de criblage pour l'agent thérapeutique
WO2013005603A1 (fr) * 2011-07-01 2013-01-10 公立大学法人横浜市立大学 Agent pour la prévention et/ou le traitement d'une inflammation allergique de la conjonctive
US9879075B2 (en) 2013-02-06 2018-01-30 Yokohama City University and Chiome Bioscience Inc. Anti-semaphorin 3A antibody and treatment of Alzheimer's disease and inflammatory immune diseases using same
AU2014221144B2 (en) * 2013-02-21 2018-03-22 Rsem, Limited Partnership Inhibition of Sema3A in the prevention and treatment of ocular hyperpermeability
ES2865488T3 (es) * 2014-09-05 2021-10-15 Rsem Lp Composiciones y métodos para el tratamiento y la prevención de la inflamación
KR101854529B1 (ko) * 2015-10-27 2018-05-04 (주) 팬젠 인간 및 마우스 Ｓｅｍａ３Ａ에 교차결합하는 항체 및 그의 용도
AU2016346595B2 (en) 2015-10-27 2019-11-14 Pangen Biotech Inc. Antibody to be cross-linked to human and mouse Sema3A, and use thereof
US10604571B2 (en) 2015-10-27 2020-03-31 Samsung Life Public Welfare Foundation Antibody to human and mouse SEMA3A and use thereof
AR122266A1 (es) 2019-05-09 2022-08-31 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares

Also Published As

Publication number Publication date
JP2022531698A (ja) 2022-07-08
TW202108621A (zh) 2021-03-01
AR122266A1 (es) 2022-08-31
PE20220287A1 (es) 2022-02-25
US20200385446A1 (en) 2020-12-10
CO2021014768A2 (es) 2021-11-19
BR112021019854A2 (pt) 2022-02-15
JP7314310B2 (ja) 2023-07-25
AU2020267874A1 (en) 2021-10-28
TWI836069B (zh) 2024-03-21
DOP2021000226A (fr) 2021-12-15
SG11202110842QA (en) 2021-10-28
JOP20210300A1 (ar) 2023-01-30
CR20210559A (es) 2021-12-23
CL2021002795A1 (es) 2022-08-05
EA202193038A1 (ru) 2022-03-30
KR20220007128A (ko) 2022-01-18
CN113795509A (zh) 2021-12-14
MX2021013671A (es) 2021-12-10
US20220144929A1 (en) 2022-05-12
WO2020225400A1 (fr) 2020-11-12
ECSP21082527A (es) 2021-12-30
IL287758A (en) 2022-01-01
EP3966239A1 (fr) 2022-03-16
JP2023130473A (ja) 2023-09-20
CA3137377A1 (fr) 2020-11-12
US11267880B2 (en) 2022-03-08

Similar Documents

Publication Publication Date Title
MA55872A (fr) Anticorps anti-sema3a et leurs utilisations pour le traitement de maladies oculaires
MA51200A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
MA52232A (fr) Inhibiteurs hétérobicycliques de mat2a et leurs méthodes d'utilisation pour le traitement du cancer
MA55325A (fr) Composés pour le traitement de maladies pd-l1
MA41060A (fr) Compositions comprenant des souches bactériennes
MA55434B1 (fr) Compositions comprenant des souches bactériennes
MA41010A (fr) Compositions comprenant des souches bactériennes
MA43982A (fr) Anticorps anti-tnf, compositions, méthodes et utilisation pour le traitement ou la prévention du diabète de type 1
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
MA51418A (fr) Inhibiteurs de glycolate oxydase pour le traitement de maladies
MA45089A (fr) Utilisation d'indazoles 2-substitués pour le traitement et la prophylaxie de maladies auto-immunes
MA52962A (fr) Méthodes de traitement du cancer avec des anticorps bispécifiques anti-cd3xmuc16 et des anticorps anti-pd-1
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA56387A (fr) Dérivés de quinazoline-4-one utiles pour le traitement de maladies et de troubles associés à braf
MA47205A (fr) Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
MA41596A (fr) Anticorps anti-tau et leurs utilisations
MA56019A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies
FR3021970B1 (fr) Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA47362A (fr) Anticorps anti-tnf, compositions et méthodes pour le traitement du rhumatisme psoriasique actif
MA47503A (fr) Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales
MA45999A (fr) Anticorps anti-pd-1, ou leurs fragments, pour le traitement de l'hépatite b
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
MA51136A (fr) Traitement des maladies monogéniques à l'aide d'un anticorps anti-cd45rc